Loading Events

Tenax Therapeutics LEVEL Setting: The Scientific Rationale for Levosimendan as the First Treatment for PH-HFpEF and the Ongoing Phase 3 LEVEL Study

Banners (31)
DATE: April 18, 2024
TIME: 10:00 AM EDT

About The Event

Join Tenax Therapeutics for LEVEL Setting, a panel of globally-recognized thought leaders in the field of heart failure, exploring the potential of TNX-103 (oral levosimendan) to treat patients with pulmonary hypertension from heart failure with preserved ejection fraction (PH-HFpEF). The event will be moderated by Stuart Rich, MD, Tenax Therapeutics’ Chief Medical Officer.

Expert panelists will review emerging science, clinical experience with TNX-103, and the evolving heart failure landscape:

  • Understanding the setting of PH-HFpEF – Sanjiv Shah, MD (Northwestern University) 
  • Mechanism of Action of Levosimendan – Daniel Burkhoff, MD, PhD (CRF/Columbia University)
  • Review of data from the Phase 2 HELP Study – Barry Borlaug, MD (Mayo Clinic)
  • Current treatment landscape in PH-HFpEF – Javed Butler, MD, MPH, MBA (Baylor Scott & White)

Following the discussion, members of Tenax Therapeutics senior management will provide a brief update on the ongoing Phase 3 LEVEL Study, followed by a Q&A session with the faculty.